Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients with Suspected Lynch Syndrome

Gastroenterology

Volumn 149, Issue 3, 2015, Pages 604e20-613.e20

  Yurgelun, Matthew B ^a,b,c   Allen, Brian ^d   Kaldate, Rajesh R ^d   Bowles, Karla R ^d   Judkins, Thaddeus ^d   Kaushik, Praveen ^d   Roa, Benjamin B ^d   Wenstrup, Richard J ^d   Hartman, Anne Renee ^d   Syngal, Sapna ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Myriad Genetic Laboratories   (United States)

Author keywords

Colon Cancer Genetics; Hereditary Nonpolyposis Colorectal Cancer; HNPCC; Inherited Cancer

Indexed keywords

APC PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; DNA GLYCOSYLASE MUTY; PROTEIN KINASE LKB1; TUMOR MARKER;

ADULT; ARTICLE; CANCER SUSCEPTIBILITY; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC SCREENING; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; LIFESPAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEXT GENERATION SEQUENCING; PATHOGENICITY; PENETRANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; GERMLINE MUTATION; HEREDITY; HIGH THROUGHPUT SEQUENCING; PEDIGREE; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; RISK ASSESSMENT; RISK FACTOR;

ADULT; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GERM-LINE MUTATION; HEREDITY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; PEDIGREE; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS;

EID: 84939839583     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.05.006     Document Type: Article

References (98)

1. G.E. Palomaki, M.R. McClain, S. Melillo, and et al. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome Genet Med 11 2009 42 65
2. H.F. Vasen, I. Blanco, K. Aktan-Collan, and et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts Gut 62 2013 812 823
3. H.D. Nelson, M. Pappas, B. Zakher, and et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation Ann Intern Med 160 2014 255 266
4. H.J. Jarvinen, M. Aarnio, H. Mustonen, and et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer Gastroenterology 118 2000 829 834
5. A.K. Win, J.P. Young, N.M. Lindor, and et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study J Clin Oncol 30 2012 958 964
6. F. Kastrinos, B. Mukherjee, N. Tayob, and et al. Risk of pancreatic cancer in families with Lynch syndrome JAMA 302 2009 1790 1795
7. S.M. Domchek, A. Bradbury, J.E. Garber, and et al. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol 31 2013 1267 1270
8. F. Kastrinos, E.W. Steyerberg, J. Balmana, and et al. Comparison of the clinical prediction model PREMM(1,2,6) and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer Gut 62 2013 272 279
9. D.E. Levy, S.D. Byfield, C.B. Comstock, and et al. Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk Genet Med 13 2011 349 355
10. N.M. Lindor, K. Rabe, G.M. Petersen, and et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X JAMA 293 2005 1979 1985
11. J. Balmana, F. Balaguer, S. Castellvi-Bel, and et al. Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients J Med Genet 45 2008 557 563
12. F. Kastrinos, E.W. Steyerberg, R. Mercado, and et al. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history Gastroenterology 140 2011 73 81
13. M. Morak, B. Heidenreich, G. Keller, and et al. Biallelic MUTYH mutations can mimic Lynch syndrome Eur J Hum Genet 22 2014 1334 1337
14. J.L. Mester, R.A. Moore, and C. Eng PTEN germline mutations in patients initially tested for other hereditary cancer syndromes: would use of risk assessment tools reduce genetic testing? Oncologist 18 2013 1083 1090
15. S.M. Weissman, C. Bellcross, C.C. Bittner, and et al. Genetic counseling considerations in the evaluation of families for Lynch syndrome-a review J Genet Couns 20 2011 5 19
16. A. Castillejo, G. Vargas, M.I. Castillejo, and et al. Prevalence of germline MUTYH mutations among Lynch-like syndrome patients Eur J Cancer 50 2014 2241 2250
17. Z.K. Stadler, K.A. Schrader, J. Vijai, and et al. Cancer genomics and inherited risk J Clin Oncol 32 2014 687 698
18. M.J. Hall, J.E. Reid, L.A. Burbidge, and et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer Cancer 115 2009 2222 2233
19. J.M. Eggington, K.R. Bowles, K. Moyes, and et al. A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes Clin Genet 86 2014 229 237
20. C.S. Richards, S. Bale, D.B. Bellissimo, and et al. ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007 Genet Med 10 2008 294 300
21. A. Renwick, D. Thompson, S. Seal, and et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles Nat Genet 38 2006 873 875
22. E.M. Stoffel, and F. Kastrinos Familial colorectal cancer, beyond Lynch syndrome Clin Gastroenterol Hepatol 12 2014 1059 1068
23. N. Chun, and J.M. Ford Genetic testing by cancer site: stomach Cancer J 18 2012 355 363
24. B. Mukherjee, J.O. Delancey, L. Raskin, and et al. Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers J Natl Cancer Inst 104 2012 953 956
25. Z.K. Stadler, P. Thom, M.E. Robson, and et al. Genome-wide association studies of cancer J Clin Oncol 28 2010 4255 4267
26. M.H. Nieuwenhuis, S. Vogt, N. Jones, and et al. Evidence for accelerated colorectal adenoma-carcinoma progression in MUTYH-associated polyposis? Gut 61 2012 734 738
27. A.K. Win, J.G. Dowty, S.P. Cleary, and et al. Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer Gastroenterology 146 2014 1208 1211 e1-e5
28. M. Casper, G. Plotz, B. Juengling, and et al. MUTYH hotspot mutations in unselected colonoscopy patients Colorectal Dis 14 2012 e238 e244
29. S.J. Lubbe, M.C. Di Bernardo, I.P. Chandler, and et al. Clinical implications of the colorectal cancer risk associated with MUTYH mutation J Clin Oncol 27 2009 3975 3980
30. A.K. Win, S.P. Cleary, J.G. Dowty, and et al. Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer Int J Cancer 129 2011 2256 2262
31. M.E. Croitoru, S.P. Cleary, N. Di Nicola, and et al. Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk J Natl Cancer Inst 96 2004 1631 1634
32. N. Jones, S. Vogt, M. Nielsen, and et al. Increased colorectal cancer incidence in obligate carriers of heterozygous mutations in MUTYH Gastroenterology 137 2009 489 494 494 e1; quiz 725-726
33. F. Balaguer, S. Castellvi-Bel, A. Castells, and et al. Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study Clin Gastroenterol Hepatol 5 2007 379 387
34. P. Peterlongo, N. Mitra, S. Chuai, and et al. Colorectal cancer risk in individuals with biallelic or monoallelic mutations of MYH Int J Cancer 114 2005 505 507
35. M. Robson Multigene panel testing: planning the next generation of research studies in clinical cancer genetics J Clin Oncol 32 2014 1987 1989
36. D. Cragun, C. Radford, J.S. Dolinsky, and et al. Panel-based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a US laboratory Clin Genet 86 2014 510 520
37. T. Walsh, S. Casadei, M.K. Lee, and et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing Proc Natl Acad Sci U S A 108 2011 18032 18037
38. A.W. Kurian, E.E. Hare, M.A. Mills, and et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment J Clin Oncol 32 2014 2001 2009
39. N. Tung, C. Battelli, B. Allen, and et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel Cancer 121 2015 25 33
40. J.P. Struewing, P. Hartge, S. Wacholder, and et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews N Engl J Med 336 1997 1401 1408
41. K.A. Metcalfe, A. Poll, R. Royer, and et al. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women J Clin Oncol 28 2010 387 391
42. B.B. Roa, A.A. Boyd, K. Volcik, and et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2 Nat Genet 14 1996 185 187
43. M.R. McClain, G.E. Palomaki, K.L. Nathanson, and et al. Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications Genet Med 7 2005 28 33
44. J.E. Garber, and S. Syngal One less thing to worry about: the shrinking spectrum of tumors in BRCA founder mutation carriers J Natl Cancer Inst 96 2004 2 3
45. H.F. Vasen, P. Watson, J.P. Mecklin, and et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC Gastroenterology 116 1999 1453 1456
46. R.C. Fitzgerald, R. Hardwick, D. Huntsman, and et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research J Med Genet 47 2010 436 444
47. M.J. Hall, A.D. Forman, R. Pilarski, and et al. Gene panel testing for inherited cancer risk J Natl Compr Canc Netw 12 2014 1339 1346
48. C.J. Gallego, B.H. Shirts, C.S. Bennette, and et al. Next-generation sequencing panels for the diagnosis of colorectal cancer and polyposis syndromes: a cost-effectiveness analysis J Clin Oncol 33 2015 2084 2091
49. R.L. Ward, S. Hicks, and N.J. Hawkins Population-based molecular screening for Lynch syndrome: implications for personalized medicine J Clin Oncol 31 2013 2554 2562
50. D. Cragun, R.D. DeBate, S.T. Vadaparampil, and et al. Comparing universal Lynch syndrome tumor-screening programs to evaluate associations between implementation strategies and patient follow-through Genet Med 16 2014 773 782
51. L.C. Beamer, M.L. Grant, C.R. Espenschied, and et al. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results J Clin Oncol 30 2012 1058 1063
52. L. Moreira, F. Balaguer, N. Lindor, and et al. Identification of Lynch syndrome among patients with colorectal cancer JAMA 308 2012 1555 1565
53. L. Perez-Carbonell, C. Ruiz-Ponte, C. Guarinos, and et al. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer Gut 61 2012 865 872
54. H. Hampel, W.L. Frankel, E. Martin, and et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer J Clin Oncol 26 2008 5783 5788
55. NCCN Clinical Practice Guidelines in Oncology. Genetic/familial high-risk assessment: colorectal. Version 2.2014. Available: http://www.nccn.org/professionals/physician-gls/pdf/genetics-colon.pdf. Accessed: January 20, 2015.
56. NCCN Clinical Practice Guidelines in Oncology. Genetic/familial high-risk assessment: breast and ovarian. Version 2.2014. Available: http://www.nccn.org/professionals/physician-gls/pdf/genetics-screening.pdf. Accessed: January 20, 2015.
57. H. Li, and R. Durbin Fast and accurate short read alignment with Burrows-Wheeler transform Bioinformatics 25 2009 1754 1760
58. J.M. Eggington, K.R. Bowles, K. Moyes, and et al. A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes Clin Genet 86 2014 229 237
59. C.S. Richards, S. Bale, D.B. Bellissimo, and et al. ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007 Genet Med 10 2008 294 300
60. N. Al-Tassan, N.H. Chmiel, J. Maynard, and et al. Inherited variants of MYH associated with somatic G: C - >T: A mutations in colorectal tumors Nat Genet 30 2002 227 232
61. S. Jones, P. Emmerson, J. Maynard, and et al. Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G: C - >T: A mutations Hum Mol Genet 11 2002 2961 2967
62. J.R. Sampson, and N. Jones MUTYH-associated polyposis Best Pract Res Clin Gastroenterol 23 2009 209 218
63. J.J. Warren, T.J. Pohlhaus, A. Changela, and et al. Structure of the human MutSalpha DNA lesion recognition complex Mol Cell 26 2007 579 592
64. D.E. Goldgar, D.F. Easton, G.B. Byrnes, and et al. Genetic evidence and integration of various data sources for classifying uncertain variants into a single model Hum Mutat 29 2008 1265 1272
65. D.F. Easton, A.M. Deffenbaugh, D. Pruss, and et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes Am J Hum Genet 81 2007 873 883
66. J. Wijnen, P.M. Khan, H. Vasen, and et al. Majority of hMLH1 mutations responsible for hereditary nonpolyposis colorectal cancer cluster at the exonic region 15-16 Am J Hum Genet 58 1996 300 307
67. C. Pagenstecher, M. Wehner, W. Friedl, and et al. Aberrant splicing in MLH1 and MSH2 due to exonic and intronic variants Hum Genet 119 2006 9 22
68. T.E. Raevaara, C. Vaccaro, W.M. Abdel-Rahman, and et al. Pathogenicity of the hereditary colorectal cancer mutation hMLH1 del616 linked to shortage of the functional protein Gastroenterology 125 2003 501 509
69. B. Liu, R.E. Parsons, S.R. Hamilton, and et al. hMSH2 mutations in hereditary nonpolyposis colorectal cancer kindreds Cancer Res 54 1994 4590 4594
70. G. Aceto, M.C. Curia, S. Veschi, and et al. Mutations of APC and MYH in unrelated Italian patients with adenomatous polyposis coli Hum Mutat 26 2005 394
71. A.M. Russell, J. Zhang, J. Luz, and et al. Prevalence of MYH germline mutations in Swiss APC mutation-negative polyposis patients Int J Cancer 118 2006 1937 1940
72. J. Auclair, M.P. Busine, C. Navarro, and et al. Systematic mRNA analysis for the effect of MLH1 and MSH2 missense and silent mutations on aberrant splicing Hum Mutat 27 2006 145 154
73. G. Casey, N.M. Lindor, N. Papadopoulos, and et al. Conversion analysis for mutation detection in MLH1 and MSH2 in patients with colorectal cancer JAMA 293 2005 799 809
74. G. Chenevix-Trench, A.B. Spurdle, M. Gatei, and et al. Dominant negative ATM mutations in breast cancer families J Natl Cancer Inst 94 2002 205 215
75. J.L. Bernstein, S. Teraoka, M.C. Southey, and et al. Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry Hum Mutat 27 2006 1122 1128
76. E.V. Koonin, S.F. Altschul, and P. Bork BRCA1 protein products. functional motifs Nat Genet 13 1996 266 268
77. T. Huyton, P.A. Bates, X. Zhang, and et al. The BRCA1 C-terminal domain: structure and function Mutat Res 460 2000 319 332
78. N. Mirkovic, M.A. Marti-Renom, B.L. Weber, and et al. Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition Cancer Res 64 2004 3790 3797
79. A.L. Moisio, H. Jarvinen, and P. Peltomaki Genetic and clinical characterisation of familial adenomatous polyposis: a population based study Gut 50 2002 845 850
80. H. Nakagawa, J.C. Lockman, W.L. Frankel, and et al. Mismatch repair gene PMS2: disease-causing germline mutations are frequent in patients whose tumors stain negative for PMS2 protein, but paralogous genes obscure mutation detection and interpretation Cancer Res 64 2004 4721 4727
81. J. Auclair, D. Leroux, F. Desseigne, and et al. Novel biallelic mutations in MSH6 and PMS2 genes: gene conversion as a likely cause of PMS2 gene inactivation Hum Mutat 28 2007 1084 1090
82. L. Senter, M. Clendenning, K. Sotamaa, and et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations Gastroenterology 135 2008 419 428
83. C.P. Vaughn, J. Robles, J.J. Swensen, and et al. Clinical analysis of PMS2: mutation detection and avoidance of pseudogenes Hum Mutat 31 2010 588 593
84. J.C. Herkert, R.C. Niessen, M.J. Olderode-Berends, and et al. Paediatric intestinal cancer and polyposis due to bi-allelic PMS2 mutations: case series, review and follow-up guidelines Eur J Cancer 47 2011 965 982
85. T.E. Raevaara, M.K. Korhonen, H. Lohi, and et al. Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1 Gastroenterology 129 2005 537 549
86. M.F. Blasi, I. Ventura, G. Aquilina, and et al. A human cell-based assay to evaluate the effects of alterations in the MLH1 mismatch repair gene Cancer Res 66 2006 9036 9044
87. J.R. Sampson, S. Dolwani, S. Jones, and et al. Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH Lancet 362 2003 39 41
88. I. Tournier, M. Vezain, A. Martins, and et al. A large fraction of unclassified variants of the mismatch repair genes MLH1 and MSH2 is associated with splicing defects Hum Mutat 29 2008 1412 1424
89. N. Rahner, N. Friedrichs, M. Wehner, and et al. Nine novel pathogenic germline mutations in MLH1, MSH2, MSH6 and PMS2 in families with Lynch syndrome Acta Oncol 46 2007 763 769
90. J. Trojan, S. Zeuzem, A. Randolph, and et al. Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system Gastroenterology 122 2002 211 219
91. Z.Q. Yuan, N. Wong, W.D. Foulkes, and et al. A missense mutation in both hMSH2 and APC in an Ashkenazi Jewish HNPCC kindred: implications for clinical screening J Med Genet 36 1999 790 793
92. W.D. Foulkes, I. Thiffault, S.B. Gruber, and et al. The founder mutation MSH2∗1906G - >C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population Am J Hum Genet 71 2002 1395 1412
93. R.S. Williams, M.S. Lee, D.D. Hau, and et al. Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1 Nat Struct Mol Biol 11 2004 519 525
94. P.K. Lovelock, A.B. Spurdle, M.T. Mok, and et al. Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants? Breast Cancer Res 9 2007 R82
95. S. Chang, R.H. Wang, K. Akagi, and et al. Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155 Nat Med 17 2011 1275 1282
96. L. Mohammadi, M.P. Vreeswijk, R. Oldenburg, and et al. A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example BMC Cancer 9 2009 211
97. E. Ricevuto, H. Sobol, D. Stoppa-Lyonnet, and et al. Diagnostic strategy for analytical scanning of BRCA1 gene by fluorescence-assisted mismatch analysis using large, bifluorescently labeled amplicons Clin Cancer Res 7 2001 1638 1646
98. T. Judkins, B. Leclair, K. Bowles, and et al. Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk BMC Cancer 15 2015 215